Iridex to Present at the Sidoti Year-End Virtual Investor Conference
Rhea-AI Summary
Iridex (NASDAQ: IRIX) will participate in the Sidoti Year-End Virtual Investor Conference with management presenting on Thursday, December 11, 2025 at 10:45 AM ET. Interested parties can access a live and archived webcast via the company’s Investor Relations Event Calendar at www.IRIDEX.com. The presentation provides investors a direct opportunity to hear company updates and ask questions during the scheduled webcast.
Positive
- None.
Negative
- None.
News Market Reaction – IRIX
In the Dec 5 session, IRIX gained 1.17%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Q3 earnings | Positive | +8.2% | Q3 2025 revenue growth with improved adjusted EBITDA and lower operating expenses. |
| Oct 28 | Earnings scheduling | Neutral | +2.0% | Announcement of Q3 2025 results release and investor conference call timing. |
| Sep 09 | Nasdaq compliance | Positive | -2.8% | Formal notification of regained compliance with Nasdaq equity listing requirements. |
| Aug 12 | Q2 earnings | Negative | -9.2% | Q2 2025 results with net loss and lower gross margin despite revenue growth. |
| Jul 29 | Earnings scheduling | Neutral | -0.7% | Scheduling of Q2 2025 results release and associated investor conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and compliance updates often drive notable moves, with mostly aligned price reactions, while conference scheduling releases tend to have smaller impacts.
Over the last six months, IRIDEX reported Q2 and Q3 2025 results, showing revenue growth (Q2 $13.6M, Q3 $12.5M) and improving adjusted EBITDA, alongside reduced operating expenses. Nasdaq listing compliance was regained with stockholders’ equity above the $2.5M threshold. Pre-earnings conference-call announcements produced modest moves. Today’s conference participation notice continues the pattern of investor-outreach events following a period of operational improvement and restored listing compliance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Sidoti Year-End Virtual Investor Conference.
Management is scheduled to present on Thursday, December 11 at 10:45 am ET. Interested parties may access a live and archived webcast of the presentation on the “Event Calendar” page of the “Investors” section of the company’s website at www.IRIDEX.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
Media Contact
Joan Stauffer
jstauffer@iridex.com
For more information about Iridex technologies, visit www.iridex.com.
Iridex, the Iridex logo, MicroPulse®, the MicroPulse logo, Cyclo G6, MicroPulse P3®, and G-Probe® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.
